Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Bone Marrow Neoplasms × ruxolitinib × Clear all

Status

Active not recruiting 1

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Conditions

Primary Myelofibrosis 38 Myeloproliferative Disorders 29 Polycythemia Vera 27 Leukemia, Myeloid, Acute 20 Precursor Cell Lymphoblastic Leukemia-Lymphoma 17 Leukemia 15 Myelodysplastic Syndromes 13 Thrombocythemia, Essential 12 Multiple Myeloma 9 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 8 Breast Neoplasms 8 Recurrence 7 Neoplasms 7 Myelodysplastic-Myeloproliferative Diseases 7 Leukemia, Myelomonocytic, Chronic 7 Graft vs Host Disease 7 Pancreatic Neoplasms 6 Hematologic Neoplasms 6 Prostatic Neoplasms 5 Lymphoma, Non-Hodgkin 5 Lymphoma 5 Leukemia, Myeloid, Chronic-Phase 5 Leukemia, Lymphocytic, Chronic, B-Cell 5 Hodgkin Disease 5 Hematologic Diseases 5 Thrombocytosis 4 Carcinoma, Non-Small-Cell Lung 4 Bone Marrow Diseases 4 Triple Negative Breast Neoplasms 3 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3

Interventions

Lenalidomide 2 Dexamethasone 2 Bortezomib 2 ruxolitinib 1 darinaparsin 1 carfilzomib 1 belinostat 1 Stem Cell Transplantation 1 SCIO-469 1 Low-Level Light Therapy 1 Hydroxyurea 1 Cyclophosphamide 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04217356 2026-01-26

ALLO-BAT

University Health Network, Toronto

Active not recruiting

Bone Marrow Neoplasms, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡